Login to Your Account

Nastech, Merck In Obesity Deal Worth Up To $346M

By Karen Pihl-Carey

Tuesday, September 28, 2004
In what its CEO called the most significant transaction in the history of the company, Nastech Pharmaceutical Co. Inc. formed a potential $346 million global alliance with Merck & Co. Inc. to develop and commercialize Peptide YY 3-36 Nasal Spray (PYY) for obesity. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription